# Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

> **NCT06958315** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Atherosclerotic Vascular Disease
- Heterozygous Familial Hypercholesterolemia

## Interventions

- **OTHER:** Inclisiran

## Key facts

- **NCT ID:** NCT06958315
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958315, "Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06958315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*